Nchi: Australia
Lugha: Kiingereza
Chanzo: Department of Health (Therapeutic Goods Administration)
Insulin aspart
Novo Nordisk Pharmaceuticals Pty Ltd
Medicine Registered
Product Information NovoRapid-NovoMix pi3a.doc Page 1 of 17 PRODUCT INFORMATION INSULIN ASPART NOVORAPID ® 10ML VIAL NOVORAPID ® PENFILL ® 3ML NOVORAPID ® FLEXPEN ® 3ML NOVOMIX ® 30 PENFILL ® 3ML NOVOMIX ® 30 FLEXPEN ® 3ML NAME OF THE MEDICINE Insulin aspart Insulin aspart (rys) has the empirical formula C 256 H 381 N 65 O 79 S 6 and a molecular weight of 5825.8. CAS No.: 116094-23-6 DESCRIPTION Insulin aspart is a rapid-acting analogue of human insulin that rapidly lowers blood glucose. Insulin aspart is homologous with human insulin with the exception of a substitution of the amino acid proline by aspartic acid at position 28 on the B-chain. The unique structure of insulin aspart increases the rate of absorption from a subcutaneous injection site, giving a faster onset of action, an earlier peak effect and a shorter duration of action than soluble human insulin. Insulin aspart should be given immediately before a meal or, when necessary, after the start of a meal. Insulin aspart is produced by recombinant DNA technology using _Saccharomyces cerevisiae_. One unit of insulin aspart corresponds to 6 nmol, 0.035 mg salt-free anhydrous insulin aspart. NovoRapid ® is a sterile, clear, colourless, aqueous, neutral solution of insulin aspart (B28 Asp) 100 U/mL. NovoRapid is a solution for injection. Product Information NovoRapid-NovoMix pi3a.doc Page 2 of 17 NovoRapid also contains the following inactive ingredients: glycerol, phenol, meta-cresol, zinc chloride, dibasic sodium phosphate dihydrate, sodium chloride, sodium hydroxide, hydrochloric acid and water for injections. NovoMix ® 30 is a white suspension for subcutaneous injection consisting of 30% soluble insulin aspart and 70% protamine-crystallised insulin aspart. This is a biphasic insulin preparation (NovoMix 30) which produces insulin pl Soma hati kamili